Meridian Medical Technologies Inc.

Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, 3M, Inhalation, Pfizer, CDMO, JPMorgan Chase, Chase Bank, Health technology, Drug delivery, Research, NYSE, Kirkland & Ellis, Multimedia, Administration, PFE, Meridian Medical Technologies Inc., Pharmaceutical industry, Meridian, Kindeva

Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.

Key Points: 
  • Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.
  • The combination has created a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
  • The combination will operate under the Kindeva name, with Meridian operating as, Meridian Medical Technologies, a Kindeva Company.
  • The combination of Kindeva and Meridian creates a clear market leader in the drug-device CDMO sector.

Kaléo Adds Chief Business Officer to Executive Team

Retrieved on: 
Tuesday, September 27, 2022
University of Bridgeport, Meridian Medical Technologies Inc., FDA, Business administration, Food, Acquisition, King Pharmaceuticals, Business, Baxter International, Regulation of tobacco by the U.S. Food and Drug Administration, Master of Business Administration, Trustee, GLOBE, McCombs School of Business, University, Suzuki Aerio, Pharmaceutical industry

Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kalo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of its new Chief Business Officer.

Key Points: 
  • Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kalo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of its new Chief Business Officer.
  • Ted A. Marcuccio has been named Kalos Chief Business Officer responsible for business development and key strategic growth initiatives.
  • Mr. Marcuccio previously held a similar role at Summit Biosciences prior to joining Kalo.
  • Ted is a seasoned business development professional with experience across a variety of pharmaceutical sectors including drug delivery.

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Retrieved on: 
Thursday, June 23, 2022
Biomedical Advanced Research and Development Authority, Government, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Leadership, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, Documentation, Orthopoxvirus, Human services, GLOBE, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, CEO, Cowpox, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, Public health, FDA, COVID-19, BARDA, IV, Health Canada, LLC, Virus, Patient, Xi, Risk, US Foods, Vaccine, Human, Research, Meridian Medical Technologies Inc., Ix, Development, Vaccinia, EMA, Assistant, Military personnel, Pharmaceutical industry, Meridian

Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.

Key Points: 
  • Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.
  • The orders from the new international jurisdictions represent the first procurements of oral TPOXX (tecovirimat) directly in response to the evolving global monkeypox outbreak.
  • SIGA currently expects to deliver approximately $4 million of oral TPOXX (tecovirimat) under the two new contracts within the next 45 days.
  • With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2 million of oral TPOXX (tecovirimat).

SIGA Reports Financial Results for Three Months Ended March 31, 2022

Retrieved on: 
Thursday, May 5, 2022
Xi, Development, Infection, Contract, Human, Annual report, Monkeypox, SIGA Technologies, Vii, Risk, Smallpox, Forward-looking statement, Immune system, European Medicines Agency, Director, Company, Immunotherapy, Neoplasm, FDA, Ix, Meridian Medical Technologies Inc., Executive order, Government, Health Canada, Research, Public Health Agency of Canada, Vaccinia, Income, Private Securities Litigation Reform Act, EMA, Policy, Genome, Time, CMOS, MAA, Vaccine, IV, PHAC, Protein, Documentation, Exercise, Board, BARDA, COVID-19, Food, Cancer, Patent, Investor relations, Phrase, Conference, Vaccination, Public Health Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Cowpox, Construction, Pharmaceutical industry, Meridian, EU

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2022.

Key Points: 
  • The special dividend is payable on June 2, 2022 to shareholders of record at the close of business on May 17, 2022.
  • In January 2022, the European Medicines Agency(EMA) approved the marketing authorisation application (MAA) for oral Tecovirimat SIGA, the same formulation that was approved by theU.S.
  • In January 2022, SIGA announced a research collaboration with Bioarchitech, aUnited Kingdom-based biotech company developing immunotherapy for the treatment of cancer.
  • During the first quarter of 2022, SIGA repurchased approximately 1.0 million shares of its common stock, for approximately $6.6 million.

GT Medical Technologies Announces 2021 GammaTile® Therapy ELITE Member Roster for Use of Its Innovative Brain Tumor Treatment

Retrieved on: 
Tuesday, February 22, 2022
University, Twitter, M Health Fairview, Department, MPH, Radiation therapy, Brain, Radiation, Associate professor, Cancer, University of Kansas Health System, Glioblastoma, Meningioma, ELITE, LinkedIn, Multimedia, Meridian Medical Technologies Inc., FDA, Patient, Pleasure, Vidant Medical Center, Memorial Sloan Kettering Cancer Center, Survival, Technology, Standard of care, CEO, Emory Healthcare, NorthShore University HealthSystem, Health, Hospital, Medical imaging, Pharmaceutical industry, MD

TEMPE, Ariz., Feb. 22, 2022 /PRNewswire/ -- GT Medical Technologies Inc ., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.

Key Points: 
  • TEMPE, Ariz., Feb. 22, 2022 /PRNewswire/ -- GT Medical Technologies Inc ., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.
  • GammaTile ELITE institutions share GT Medical Technologies' purpose of improving the lives of patients with brain tumors.
  • GammaTile Therapy features a bioresorbable, conformable, 3D-collagen tile that is implanted in the last five minutes of brain tumor removal surgery.
  • GT Medical Technologies was founded by fiveArizonabrain tumor specialists in 2017 to overcome the limitations of the current standard of care for patients with brain tumors.

Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath® Initial Specimen Diversion Device®

Retrieved on: 
Wednesday, December 15, 2021
Well, Solution, Hospital, ISDT, Board of directors, FDA, Invention, Intellectual property, Board, Awareness, Ownership, Meridian Medical Technologies Inc., Magnolia, Sepsis, CEO, Research, Patient, Vancomycin, Knowledge, NOAAS Bell M. Shimada (R 227), Patent, Health care, Blood culture, Infection, Collection, Multimedia, Patient safety, MHA, Analysis, Risk management, Technology, View, Medical device, Pharmaceutical industry, Vaccine, Silviculture

Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

Key Points: 
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.
  • HPIC is a reciprocal insurance company providing professional liability and worker's compensation insurance to healthcare providers and healthcare systems.
  • Rupp ME, Cavalieri RJ, Marolf C, Lyden E. Reduction in blood culture contamination through use of Initial Specimen Diversion Device.
  • Tompkins LS, Madison A, Schaffner T, Tran J, Ang P. Eliminating blood culture contamination with an Initial-Specimen Diversion Device.

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

Retrieved on: 
Wednesday, December 1, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Sale, CEO, Risk, DND, Meridian Medical Technologies Inc., Interest, Annual report, Forward-looking statement, Public Health Agency of Canada, SIGA Technologies, United States Department of Defense, Emergency medical services, Project Bioshield Act, Partnership, Health Canada, Human, SEC, Public Health Agency, IV, U.S. Securities and Exchange Commission, Vaccine, Vaccination, PHAC, Policy, Research, Government of Canada, Smallpox, LLC, GLOBE, FDA, National security, Infection, NASDAQ, Pharmaceutical industry

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Health Canada has approved oral TPOXX (tecovirimat) as an extraordinary use new drug.

Key Points: 
  • NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Health Canada has approved oral TPOXX (tecovirimat) as an extraordinary use new drug.
  • Specifically, Health Canada has authorized the use of oral TPOXX for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.
  • The approval ensures that we can continue to supply oral TPOXX to both the DND and the Public Health Agency of Canada (PHAC) for stockpiling as a key countermeasure, said Dr. Phil Gomez, CEO of SIGA Technologies.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

Magnolia Medical Further Strengthens Executive Management Team with the Addition of Silicon Valley Financial Leader, Patrick O'Malley, as Chief Financial Officer

Retrieved on: 
Thursday, October 28, 2021
Meridian Medical Technologies Inc., Infection, Research, Technology, Seagate Technology, Seagate, O'Malley, Invention, NASDAQ, FDA, Sepsis, Blood culture, NYSE, Collection, Patent, CEO, ISDT, Growth, Multimedia, Christopher O'Malley, Intellectual property, AVYA, Medical device, Management, Pharmaceutical industry

Before joining Magnolia, O'Malley was Chief Financial Officer of Avaya (NYSE: AVYA) where he led the financial restructuring of the company's $4 billion capital structure before taking the company public on the NYSE.

Key Points: 
  • Before joining Magnolia, O'Malley was Chief Financial Officer of Avaya (NYSE: AVYA) where he led the financial restructuring of the company's $4 billion capital structure before taking the company public on the NYSE.
  • Prior to Avaya, O'Malley was Chief Financial Officer at Seagate Technology (NASDAQ: STX).
  • During his tenure as an executive, Seagate's public market value grew from $1 billion to over $12 billion.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development

Retrieved on: 
Tuesday, October 26, 2021
Meridian Medical Technologies Inc., Infection, Engineering, Technology, Hypertension, Invention, Patient, FDA, Sepsis, Blood culture, Bishop, Quality assurance, Senior, Strategic planning, Collection, Patent, Magnolia, CEO, ISDT, COO, Regulatory affairs, Development, Acquisition, D, Medical device, Management, Pharmaceutical industry

Mr. Bishop brings extensive and diverse medical device experience to Magnolia Medical.

Key Points: 
  • Mr. Bishop brings extensive and diverse medical device experience to Magnolia Medical.
  • Prior to joining Magnolia Medical, Bishop served as Vice President of Operations and R&D for Vascular Dynamics, an emerging growth medical technology company focused on innovative implantable devices to address the unmet need for patients with uncontrolled hypertension.
  • Prior, Bishop was a member of the Executive Leadership Team at Suneva Medical Corporation where he was accountable for strategy and execution of all Operations and Research and Development activities.
  • In his role as a member of the Magnolia Medical executive leadership team, Bishop is responsible for the Operations, Product Development, Quality Assurance, and Regulatory Affairs teams.

Pritzker Levine LLP, Robbins Geller Rudman & Dowd LLP, Sharp Law, LLP, Burns Charest LLP and Keller Rohrback L.L.P., Announce a $345 Million Class Action Settlement with Defendant Pfizer Inc. for Purchasers of EpiPen, EpiPen Jr. and/or their Authorized Ge

Retrieved on: 
Wednesday, August 4, 2021
Organized crime, Articles, Crime, Adrenaline, Epinephrine autoinjector, First aid, Sanofi, Type I hypersensitivity, Racketeer Influenced and Corrupt Organizations Act

This includes:

Key Points: 
  • This includes:
    This lawsuit asserts that Defendants violated certain state antitrust and federal racketeering laws, harming competition, and causing class members to overpay for EpiPen products.
  • No one is claiming that EpiPen products are unsafe or ineffective.
  • Plaintiffs are still litigating against other Defendants with a trial scheduled for January 24, 2022.
  • If you fall into one of these categories you are a Class Member (unless you are excluded by the class definition, available on the settlement website) and you may:
    Object.